Compromised circadian function in Parkinson's disease: Enucleation augments disease severity in the unilateral model

Behavioural Brain Research

Volumn 193, Issue 1, 2008, Pages 37-47

  Willis, Gregory L ^a   Kelly, Adelheid M A ^a   Kennedy, Gerard A ^b  

^a Neurosciences Section   (Australia)

^b VICTORIA UNIVERSITY   (Australia)

Author keywords

Circadian; Dopamine; Enucleation; LH lesions; Melatonin; Parkinson's disease

Indexed keywords

LEVODOPA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC DENERVATION; CONTROLLED STUDY; DISEASE SEVERITY; ENUCLEATION; HEMISPHERE; HYPOTHALAMUS NUCLEUS; MALE; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE ENUCLEATION; FUNCTIONAL LATERALITY; HYPOTHALAMIC AREA, LATERAL; INJECTIONS, INTRAPERITONEAL; LEVODOPA; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA;

EID: 47849131692     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.04.017     Document Type: Article

References (82)

1. Abbott A. While you were sleeping. Nature 437 (2006) 1220-1222
2. Abbruzzese G., and Beradelli A. Sensorimotor integration in movement disorders. Mov. Disord. 18 3 (2003) 231-240
3. Amick M.M., Cronin-Golomb A., and Gilmore G.C. Visual processing of rapidly presented stimuli is normalized in Parkinson's disease when proximal stimulus strength is enhanced. Vision Res. 43 26 (2003) 2827-2835
4. Anton-Tay F., and Wurtman R.J. Stimulation of hydroxyindole-o-methyl transferase activity in hamster pineal glands by blinding or continuous darkness. Endocrinology 82 6 (1968) 145-146
5. Arnulf I., Konofal E., Merino-Andreu M., Houeto J.L., Mesnage V., Welter M.L., et al. Parkinson's disease and sleepiness. An integral part of PD. Neurology 58 (2002) 1019-1024
6. Balagura S., Wilcox R.H., and Coscina D.V. The effects of diencephalic lesions on food intake and motor activity. Physiol Behav 4 (1969) 629-633
7. Barcia C., Bautista V., Sarchez-Bahillo A., Fernandez-Villalba E., Navarro-Ruis J.M., Barreiro A.F., et al. Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys. Neuroendocrinology 78 (2003) 118-128
8. Blazejova K., Nevsimalova S., Illnerova H., Hajek I., and Sanka K. Sleep disorders and the 24 hour profile of melatonin and cortisol. Sb Lek 101 4 (2000) 347-351
9. Bodis-Wollner I., and Tzelepi A. The push-pull action of dopamine on spatial tuning of the members retina: the effects of dopaminergic deficiency and selective D1, and D2 receptor ligands on the pattern electroretinogram. Vision Res 38 10 (1998) 1479-1481
10. Boeve B.F., Silber M.H., and Ferman T.J. REM sleep behaviour disorders in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatr Neurol 17 (2004) 146-157
11. Bordet R., Devos D., Brigue S., Touitou Y., Guieu J.D., Libersa C., et al. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clinical Neuropharmacol 26 2 (2003) 65-72
12. Burton S., Daya S., and Potgeiter B. Melatonin modulates apomorphine-induced rotational behaviour. Experientia 47 (1991) 466-469
13. Calne D.B., and Langston J.W. Aetiology of Parkinson's disease. Lancet 2 8365-8366 (1983) 1457-1459
14. Catala M.D., Canete-Nicolas C., Fradi A., Tara Zona P.J., Tormos J.M., and Pascual-Leone A. Melatonin levels in Parkinson's disease: drug therapy versus electrical stimulation of the internal globus pallidus. Exp Gerontol 32 4-5 (1997) 553-558
15. Charman W.N. Age, lens transmittance, and the possible effects of light on melatonin suppression. Opthal Physiol Opt 23 (2003) 181-187
16. Cingolani C., Rogers B., Lu L., Kachi S., Shen J., and Campochiaro P.A. Retinal degeneration from oxidative damage. Free Rad Biol Med 40 4 (2006) 660-669
17. Dabbeni-Sala F., DiSanto S., Franceschini D., Skaper S.D., and Giusti P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 15 1 (2001) 164-170
18. Danguir J., and Nicolaidis S. Cortical activity and sleep in the rat lateral hypothalamic syndrome. Brain Res 185 (1980) 305-321
19. De Butte M., Fortin T., and Pappas B.A. Pinealectomy: behavioural and neuropathological consequences in a chronic cerebral hypoperfusion model. Neurobiol Aging 23 (2002) 309-317
20. Demet E.M., Chicz-Demet A., Fallon J.H., and Sokolski K.N. Sleep deprivation therapy in depressive illness and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 23 5 (1999) 753-784
21. Deniker P., Ginestet D., and Loo H. Psychotropic drugs and mechanisms of mood regulators. Encephale 1 4 (1975) 359-362
22. Djamgoz M.B.A., Hawkins M.W., Hirano J., and Archer S.N. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res 37 24 (1997) 3509-3529
23. Dowling G.A. Sleep in older women with Parkinson's disease. J Neurosci Nursing 27 6 (1995) 355-362
24. Funatot B., Nichols W.C., Perez-Tur J., Mercier G., and Lucotte G. Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson's disease. Genet Test 10 4 (2006) 290-293
25. Guardiola-Le Maitre B. Toxicology of melatonin. J Biol Rhythms 12 60 (1997) 697-706
26. Guillilian L.A. The connections of the basal optic route (posterior accessory optic tract) and its nucleus in various mammals. J Comp Neurol 74 (1941) 367-408
27. Hamilton M.H., Garcia-Munoz M., and Arbuthnott G.W. Separation of the motor consequences from other actions of unilateral 6-hydroxydopamine lesions in the nigrostriatal neurones of rat brain. Brain Res 348 2 (1985) 220-228
28. Hamm H.E., and Menaker M. Retinal rhythms in chicks, circadian variations in melatonin and serotonin-N-acetyltransferase activity. Proc Natl Acad Sci 77 (1980) 4998-5002
29. Harrell L.E., and Balagura L.E. The effect of dark and light on the functional recovery following lateral hypothalamic lesions. Life Sci 15 (1974) 2079-2087
30. Hayhow W.R., Webb C., and Jervie A. The accessory optic fiber system in the rat. J Comp Neurol 113 (1960) 281-314
31. Hess Ch.W. Sleep disturbances and dementia. Praxis 86 (1977) 1343-1349
32. Hunter S. The rostral mesencephalan in Parkinson's disease and Alzheimer's disease. Acta Neuropathol (Berl) 68 1 (1991) 53-58
33. Hynes M.D., Lal H., and Anderson C.D. Facilitation of recovery from lateral hypothalamic syndrome by blockade of central dopaminergic receptor sites. Proceedings of 81st Annual Conference of American Psychological Association (1973) 1047-1048
34. Jackson G.R., and Owsley C. Visual dysfunction, neurodegenerative diseases and aging. Neurol Clin 21 3 (2003) 709-728
35. Jellinger K.A. Post mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms?. J Neurol Transmn 56 (1999) 1-29
36. Jin B.K., Shin D.Y., Jeong M.Y., Gwaq M.R., Baik H.W., Yoon K.S., et al. Melatonin protects nigral dopaminergic neurons from 1-methyl 1-4-phenlypyridinium (MPP+) neurotoxicity in rats. Neurosci Lett 245 (1998) 61-64
37. Joo W.S., Jin B.Y., Park C.W., Maeng S.H., and Kim Y.J. Melatonin increases striatal dopaminergic function in 6-OHDA lesioned rats. Neuroreport 9 (1998) 4123-4126
38. Kim Y.S., Joo W.S., Jin B.K., Cho Y.H., Baik H.H., and Park C.W. Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system. Neuro report 9 (1998) 2387-2390
39. Khaldy H., León J., Escames G., Bikjdaouene L., García J.J., and Acuña-Castroviejo D. Circadian rhythms of dopamine and dihydroxyphenyl acetic acid in the mouse striatum: effects of pinealectomy and of melatonin treatment. Neuroendocrinology 73 3 (2002) 201-208
40. Kremer H.P. The hypothalamic lateral tuberal nucleus: normal anatomy and changes in neurological diseases. Prog Brain Res 93 (1992) 249-261
41. Langston J.W., and Forno L.S. The hypothalamus in Parkinson's disease. Ann Neurol 3 2 (1978) 129-133
42. Lewy A.J., and Newsome D.A. Different types of melatonin circadian secretory rhythms in some blind subjects. J Clin Endocrinol Metab 56 60 (1983) 1103-1107
43. Mai J.K. The accessory optic system and the retino-hypothalamic system. A review. J Hirnforsch 19 3 (1978) 213-288
44. Marshall J.F., and Teitelbaum P. Further analysis of sensory inattention following lateral hypothalamic damage in rats. J Comp Physiol Psych 86 3 (1974) 375-395
45. Masson G., Mestre D., and Blin D. Dopaminergic modulation of visual sensitivity in man. Fundam Clin Pharmacol 7 8 (1993) 449-463
46. Mattson M.P. Infectious agents and age-related neurodegenerative disorders. Ageing Res Rev 3 1 (2004) 105-120
47. Moore R.Y. Neural control of the Pineal gland. Behavioral. Brain Res 73 (1996) 125-130
48. Moore R.Y., and Bloom F.E. Central catecholamine neuron systems: Anatomy and physiology of the dopamine systems. Ann Rev Neurosci 1 (1978) 129-169
49. Moore R.Y., Heller A., Wurtman R.J., and Axelrod J. Visual pathways mediating pineal response to environment light. Science 155 (1967) 220-223
50. Niles L.P., Brown G.M., and Mishra R.K. Effects of blinding and pinealectomy on regional brain monoamine concentrations. J Neurosci Res 10 1 (1983) 53-60
51. Nimura T., Yamaguchi K., Ando T., Shibuya S., Oikawa T., Nakagawa A., et al. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson's disease in response to subthalamic nucleus stimulants: a positron emission tomography study. J Neurosurg 103 6 (2005) 968-973
52. Okun M.S., and Watts R. Depression associated with Parkinson's disease. Clinical factors and treatment. Neurology 58 suppl. 1 (2002) 563-570
53. Oldfield B.J., Allen A.M., Davern P., Giles M.E., and Owens N.C. Lateral hypothalamic "command neurons" with axonal projections to regions involved in both feeding and thermogenesis. Eur J Neurosci 25 8 (2007) 2404-2412
54. Pellegrino L., Pellegrino A., and Cushman A. A stereotaxic atlas of the rat brain (1979), Plenum Press, New York
55. Pence S. Paw preference in rats. J Basic Clin Physiol Pharmacol 13 1 (2002) 41-49
56. Petras J.M., Bauman R.A., and Elsayed N.M. Visual system degeneration induced by blast over pressure. Toxicology 121 1 (1997) 41-49
57. Prusky G.T., Harker K.T., Douglas R.M., and Whishaw I.Q. Variation in visual acuity within pigmented, and between pigmented and albino rat strains. Behav Brain Res 136 2 (2002) 339-348
58. Reist C., Sokolski K.N., Chen C.C., Coskinas E., and Demet E.M. The effect of sleep deprivation on motor impairment and retinal adaptation in Parkinson's disease. Prog Neuro-Psychopharmacol Biol Psychiatr 19 (1995) 445-454
59. Reiter R.J. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 56 (1998) 359-384
60. Reiter R.J., Guerrero J.M., Garcia J.J., and Acuna-Castroviejo D. Reactive oxygen intermediates, molecular damage and aging. Relation to melatonin. Ann N Y Acad Sci 854 (1998) 410-424
61. Ricter C.P. Sleep and activity: their relation to the 24-hour clock. Sleep and altered states of consciousness. Proc Ass Res Nerv Ment Dis 45 (1967) 8-27
62. Rye D.B., Bliwise D.L., Dihenia B., and Gurecki P. Fast track: daytime sleepiness in Parkinson's disease. J Sleep Res 9 1 (2000) 63-69
63. Sachs C., and Jonsson G. Changes in central noradrenalin neurons alter systemic 6-hydroxydopamine administration. J Neurochem 21 (1973) 1517-1524
64. Sack R.L., Lewy A.J., Blood M.L., Keith L.D., and Nakagawa H. Circadian rhythm abnormalities in totally blind people: incidence and clinical significance 75 1 (1992) 127-134
65. Silva M.F., Faria P., Regateiro F.S., Fojaz V., Januario C., Freire A., et al. Independent patterns of damage within mango-, parvo- and kino cellular pathways in Parkinson's disease. Brain 128 PT10 (2005) 2260-2271
66. Srinivasan V. Melatonin oxidative stress and neurodegenerative diseases. Ind J Exp Biol 40 6 (2002) 668-679
67. Srinivasan V., Pandi-Perumal S., Cardinali D., Poeggeler B., and Hardeland R. Melatonin in Alzheimers's disease and other neurodegenerative disorders. Behav Brain Funct 2 1 (2006) 15
68. Teitelbaum P., and Epstein A. The lateral hypothalamic syndrome: recovery of feeding and drinking after lateral hypothalamic lesions. Psych Rev 69 (1962) 74-90
69. Ungerstedt U. 6-hydroxydopamine induced degeneration of central monoamine neurones. Eur J Pharmacol 5 (1968) 107-110
70. Wayner M.J. Specificity of behavioral regulation. Physiol Behav 12 5 (1974) 851-869
71. Willis GL. Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process, Rev Neurosci, 2008, in press.
72. Willis GL. Intravitreal injections repair Parkinson's disease. Brain Res, 2008, in press.
73. Willis G.L., and Armstrong S.M. Orphan neurones and amine excess; the functional neuropathology of Parkinsonism and neuropsychiatric disease. Brain Res Rev 27 (1998) 177-242
74. Willis G.L., and Armstrong S.M. A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol Behav 66 5 (1999) 785-795
75. Willis G.L., and Robertson A.D. Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral. 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmacol Biochem Behav 79 3 (2004) 413-429
76. Willis G.L., and Robertson A.D. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1, 2, 3 6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23. Pharmacol Biochem Behav 80 (2005) 9-26
77. Willis G.L., Singer G., and Evans B.K. Intracranial injections of 6-OHDA: comparison of the catecholamine depleting effects of different volumes and concentrations. Pharmacol Biochem Behav 5 (1976) 207-213
78. Willis G.L., and Smith G.C. Amine accumulation in behavioural pathology. Brain Res Rev 9 (1985) 109-132
79. Willis G.L., Smith G.C., and Kinchington P.C. Peripheral DA receptor blockade facilitates behavioural recovery from nigro-striatal damage. Brain Res Bull 11 (1983) 15-19
80. Willis G.L., and Turner E.J.D. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light therapy: a case series study. Chronobiol Int 24 3 (2007) 521-537
81. Yamadori T., and Yamauchi K.E. An experimental anatomical study on the optic nerve fibres in the rat: course of the accessory optic tract. Brain Res 269 1 (1983) 41-46
82. Zigmond M.J., and Stricker E.M. Deficits in feeding behavior after Intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science 177 (1972) 1211-1214